No Data
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note
10-Q: Q3 2024 Earnings Report
8-K: Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
Express News | Biofrontera Inc - Data Now Being Analyzed, Interim Results Expected November 2024
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (SBCC)
Express News | Biofrontera Inc. Announces Database Lock of Phase 3 Study of Ameluz®-Photodynamic Therapy (Pdt) in the Treatment of Superficial Basal Cell Carcinoma (Sbcc)